# Dividends Aren't Enough: Drug Services

I love cash. As an investor, nothing makes me happier than a company that returns money to shareholders, rather than spending it recklessly on a CEO's pet projects or an ill-fated acquisition. Historically, investors have often looked at a stock's dividend yield to identify these shareholder-friendly enterprises. But I prefer a slightly different metric -- one proven to further maximize investor returns.

A 2007 study in The Journal of Finance suggests that investors should also factor net share repurchases into the equation, through a metric called the net payout ratio. According to the authors of the study, this ratio not only identifies companies that are paying back investors, but also predicts future equity returns better than the dividend yield.

Let's crunch the numbers
To find the net payout yield, start by adding up all the cash the company spends on both dividends and share buybacks. Next, subtract its share issuances. Finally, divide the resulting number by the company's current market cap.

The ratio that you end up with represents the percent of each invested dollar that a company is returning to shareholders. This simple calculation handily allows us to adjust for shares issued through employee stock options and other forms of shareholder dilution. Some companies will spend a lot of money buying back shares just to counteract the dilutive effect of their stock compensation programs, without creating any value for shareholders.

Here are the net payout yields for a few companies in the pharmaceutical services industry:

Company

Net Payout Yield (TTM)

Dividend Payments (TTM)

Net Share Repurchases (TTM)

Market Cap

AmerisourceBergen (NYSE: ABC  )

6.4%

\$85

\$411

\$7,732

McKesson (NYSE: MCK  )

5.4%

\$130

\$716

\$15,781

Cardinal Health (NYSE: CAH  )

4.1%

\$253

\$190

\$10,823

Henry Schein (Nasdaq: HSIC  )

(0.6%)

\$0

(\$29)

\$4,863

Source: Capital IQ, a division of Standard & Poor's. Payout yield is author's calculation. All dollar figures in millions. Data as of Aug. 29, 2010. TTM = trailing 12 months.

It's also interesting to look at the emphasis that each company puts on dividends versus stock buybacks:

How powerful is this payout?
Based on the analysis above, AmericsourceBergen, McKesson, and Cardinal Health all look like potential buys for investors searching the pharmaceutical services industry for a stock with a solid net payout yield. As you can see from the data above, these companies have made a strong commitment to returning cash to shareholders.

Keep in mind that this data only looks at trailing-12-month numbers, so it does not correct for recent changes in a company's dividend or buyback policy. While dividends tend to remain fairly stable, share buybacks can vary substantially from year to year. Investors should also look at a company's dividend payout ratio to make sure the dividend is sustainable, and examine historical buyback patterns to ensure that the buybacks aren't a one-time event. If you can build a diversified portfolio with a few of these high-yielders, healthy returns -- and plenty of cash -- are likely to follow.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Motley Fool Hidden Gems analyst Jeremy Myers does not own shares of any company mentioned. McKesson is a Motley Fool Stock Advisor recommendation. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

### Compare Brokers

Fool Disclosure

DocumentId: 1289732, ~/Articles/ArticleHandler.aspx, 8/1/2014 11:05:36 AM

### Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

### TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.